REG - ValiRx PLC - Result of AGM

ValiRxAnnouncement

08/05/2018 12:15

2018-05-08T11:13:16.91Zreuters.comtag:reuters.com,2018-05-08:newsml_RSH3756Na:13TXT
This file is provided for EAP sample purposes only; it's structure and detail are subject to change, and should not be used as a definitive reference for actual development and processing.2018-05-08T11:13:16.91Z2018-05-08T11:13:16.91Z____UCDP:parsn_lse_10.54.4.69_1.2.37235:2019-06-08T11:13:16.910Z3RSH3756NaREG - ValiRx PLC  - Result of AGMHealthcare (TRBC level 1)Pharmaceuticals & Medical Research (TRBC level 2)Biotechnology & Medical Research (TRBC level 4)Bio Therapeutic Drugs (TRBC level 5)Western EuropeUnited KingdomEuropeSuggested SourcesNews AnnouncementsRegulatory Corporate News AnnouncementsCompany NewsEurope daily earnings hits & missesValiRx PLC








RNS Number : 3756N
ValiRx PLC
08 May 2018
 

 
 
ValiRx Plc
("ValiRx" or the "Company")
 
Result of Annual General Meeting
 
London, UK., 08 May 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that at its Annual General Meeting ("AGM") held earlier today, resolutions 1-5 were passed and resolutions 6 and 7 were withdrawn.
 
*** ENDS ***
 
For more information, please contact:




ValiRx plc


Tel: +44 (0) 20 3008 4416
www.valirx.com




Dr Satu Vainikka, Chief Executive


Tel: +44 (0) 20 3008 4416




Tarquin Edwards, Head of Communications.


Tel: +44 (0) 7879 458 364
tarquin.edwards@valirx.com




 


 




Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray/Ludovico Lazzaretti


Tel: +44 (0) 20 7213 0880




 


 




Novum Securities Limited (Broker)
Colin Rowbury


Tel: +44 (0) 20 7399 9400




 
Notes for Editors
 
About ValiRx
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
 
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
 
ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College. 
 
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.
 
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGSSAFFAFASESI